COMP360 nears launch as COMPASS Pathways eyes 2027 market entry

Compass Pathways (CMPS) is advancing its synthetic psilocybin treatment, COMP360, toward a potential 2027 launch, despite ongoing regulatory challenges related to its rescheduling by the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) approval. The company’s stock, trading near its 52-week high of $15.87, has surged 173.8% over the past year, reflecting investor optimism about its pipeline and market positioning. COMP360 is designed to treat treatment-resistant depression (TRD) with a lower annual dosing burden than Johnson & Johnson’s (J&J) SPRAVATO, which patients typically require 25 to 50 times per year, compared to an expected 2 to 4 doses annually for COMP360. This could address a significant unmet need, as TRD affects about 4 million Americans, yet only 100,000 receive SPRAVATO, a market valued at roughly $2.3 billion annually. The treatment’s pricing is anticipated to range between $50,000 and $65,000 per year, aligning with SPRAVATO’s cost, though reimbursement remains a hurdle—current reimbursement averages $250 to $300 per visit, with only 35% to 40% of SPRAVATO use covered under a buy-and-bill model. The DEA’s rescheduling timeline, mandated by statute to occur within 90 days of FDA approval, could be expedited by a February executive order urging faster action, potentially shortening the process. Meanwhile, the FDA has granted COMP360 a Breakthrough Therapy designation since 2018 and is expected to complete a rolling submission by the fourth quarter of 2024, with a review target of 1 to 2 months under a Priority Review Voucher. Clinical trials, including COMP005 and COMP006, have shown promising results, with COMP006’s 52-week data demonstrating additional benefit from a second dose after 26 weeks. Beyond TRD, COMP360 is advancing a Phase II trial for post-traumatic stress disorder (PTSD), targeting 13 million U.S. patients, including underserved groups like women survivors of sexual violence. The company also maintains a preclinical pipeline of over 1,000 compounds. With 8,000 interventional psychiatry clinics capable of administering SPRAVATO-like treatments and expanding at 500 new sites per quarter, COMP360’s adoption could depend on infrastructure and reimbursement policies. J&J’s SPRAVATO is projected to reach a $3.5 billion annual run rate by 2028, underscoring the competitive stakes for COMP360’s potential entry into the TRD market.